Synergistic in vitro interactions between (22S,23S)-3β-bromo-5α, 22,23-trihydroxystigmastan-6-one and acyclovir or foscarnet against herpes simplex virus type 1

Chemotherapy

Volumn 52, Issue 1, 2005, Pages 38-42

  Talarico, Laura B ^a   Castilla, Viviana ^a   Ramirez, Javier A ^a   Galagovsky, Lydia R ^a   Wachsman, Mónica B ^a,b  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b Laboratorio de Virologia Ciudad Autonoma de Buenos Aires   (Argentina)

Author keywords

(22S,23S) 3 bromo 5 ,22,23 trihydroxystigmastan 6 one; Antiviral drug drug combinations; Brassinosteroid derivatives; Herpes simplex

Indexed keywords

3BETA BROMO 5ALPHA,22,23 TRIHYDROXYSTIGMASTAN 6 ONE; ACICLOVIR; ANTIVIRUS AGENT; FOSCARNET; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; DRUG ACTIVITY; DRUG POTENTIATION; GENE FREQUENCY; GENE MUTATION; GENE TARGETING; HERPES SIMPLEX VIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; VIROGENESIS;

ACYCLOVIR; ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CELL PROLIFERATION; CERCOPITHECUS AETHIOPS; CHOLESTANONES; DRUG SYNERGISM; FOSCARNET; HERPESVIRUS 1, HUMAN; MOLECULAR STRUCTURE;

EID: 29344449935     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000090242     Document Type: Article

References (18)

1. Oliver NM, Collins P, Van der Meer J, Van't Wout JW: Biological and biochemical characterization of clinical isolates of herpes simplex virus type 2 resistant to acyclovir. Antimicrob Agents Chemother 1989;33:635-640.
2. Morfin F, Thouvenot D: Herpes simplex virus resistance to antiviral drugs. J Clin Virol 2003;26:29-37.
3. Edert DY, Finance CMT, Le Faou AE: Susceptibility of clinical strains of herpes simplex virus to three nucleoside analogues. Chemotherapy 2000;46:195-197.
4. Smee DF, Bailey KW, Morrison AC, Sidwell RW: Combination treatment of influenza A virus infections in cell culture and in mice with the cyclopentane neuraminidase inhibitor RWJ-2 70201 and ribavirin. Chemotherapy 2002;48:88-93.
5. Andersen JH, Jenssen H, Gutteberg TJ: Lactoferrin and lactoferricin inhibit herpes simplex 1 and 2 infection and exhibit synergy when combined with acyclovir. Antiviral Res 2003;58:209-215.
6. Buckwold VE: Implications of finding synergic in vitro drug-drug interactions between interferon-α and ribavirin for the treatment of hepatitis C virus. J Antimicrob Chemother 2004;53:413-414.
7. Wachsman MB, López EMF, Ramírez JA, Galagovsky LR, Coto CE: Antiviral effect of brassinosteroids against herpes virus and arenaviruses. Antiviral Chem Chemother 2000;11:71-77.
8. Talarico LB, Ramírez JA, Galagovsky LR, Wachsman MB: Structure-activity relationship studies in a set of new brassinosteroid derivatives assayed against herpes simplex virus type 1 and 2 in cell cultures. Med Chem Res 2002;11:434-444.
9. Wachsman MB, Ramírez JA, Galagovsky LR, Coto CE: Antiviral activity of brassinosteroids derivatives against measles virus in cell cultures. Antivir Chem Chemother 2002;13:61-66.
10. Wachsman MB, Ramírez JA, Talarico LB, Galagovsky LR, Coto CE: Antiviral activity of natural and synthetic brassinosteroids. Curr Med Chem Antiinfect Agents 2004;3:163-179.
11. Wachsman MB, Castilla V, Talarico LB, Ramírez JA, Galagovsky LR, Coto CE: Antiherpetic mode of action of (22S,23S)-3β-bromo-5α,22,23- trihydroxystigmastan-6-one in vitro. Int J Antimicrob Agents 2004;23:524-526.
12. Field HJ: Herpes simplex virus antiviral drug resistance - Current trends and future prospects. J Clin Virol 2001;21:261-269.
13. Shin JK, Cai GY, Weinberg A, Leary JJ, Levin MJ: Frequency of acyclovir-resistant herpes simplex virus in clinical specimens and laboratory isolates. J Clin Microbiol 2001;39:913-917.
14. Chilukuri S, Rosen T: Management of acyclovir-resistant herpes simplex virus. Dermatol Clin 2003;21:311-320.
15. Teme Centurión OM, Galagovsky LR: Alternative synthesis of 24(S)-homoethylcastasterone from stigmasterol. Anal Asoc Quím Arg 1998;86:104-109.
16. Denizot F, Lang R: Rapid colorimetric assay for cell growth and survival. J Immunol Methods 1986;89:271-277.
17. Prichard MN, Shipman C: A three-dimensional model to analyze drug-drug interactions. Antiviral Res 1990;14:181-206.
18. Michelini FM, Ramírez JA, Berra A, Galagovsky LR, Alché LE: In vitro and in vivo antiherpetic activity of three new synthetic brassinosteroid analogues. Steroids 2004;69:713-720.